Health ❯ Healthcare ❯ Chronic Conditions

Diabetes

Type 2 Diabetes Management Strategies Type 1 Diabetes Insulin Management GLP-1 Drugs Weight Management Treatment Options Blood Sugar Management Insulin Therapy Obesity Obesity Management Type 2 Diabetes Treatments Continuous Glucose Monitoring Medication Management GLP-1 Medications Medication Effects GLP-1 Receptor Agonists Complications Type 2 Diabetes Management Hypoglycemia Management Hypertension Kidney Disease Diabetic Ketoacidosis Blood Glucose Monitoring Januvia Diabetes Mellitus Semaglutide and Diabetes Diabetes Medications Insulin Pumps Oncology Diabetes Treatment Semaglutide Medications Heart Problems Patient Experiences Medication Access Steroid-Induced Diabetes Medications Cognitive Decline Semaglutide Insulin Supply Antidiabetic Medications GLP-1 Hypoglycemia and Hyperglycemia Metabolic Disorders Eye Care Prediabetes Weight Loss and Diabetes Type 2 Diabetes Prevention Mounjaro Risks Complications of Diabetes Monitoring Devices Monitoring Technologies Glucose Monitoring Hypoglycemia Management Medication Use Tirzepatide GLP-1 Therapies Hypertension Management Diabetic Foot Ulcers Heart Disease Medication Interaction Diabetes Prevention Type 2 Diabetes Medication Long-term Management Cardiometabolic Risk Diabetic Foot Complications Diabetic Eye Diseases Type 1 Diabetes Treatments GLP-1 Medications for Diabetes Vision Impairment Diabetes Types GLP-1 for Diabetes Management Kidney Complications Management of Blood Sugar Levels Anti-Diabetic Drugs Symptoms of Diabetes Diabetic Complications Blood Pressure Management GLP-1 Agonists Visceral Fat Type-I Diabetes Alzheimer's Disease Insulin Access Type 2 Diabetes Treatment Weight Loss Treatments Diabetes Management Fibromyalgia Insulin Treatment Ozempic Screening Tests High-Risk Diabetes Stress Disorders Endocrinology GLP-1 Benefits Type 1 Diabetes Management Frozen Shoulder GLP-1 Coverage Trends Insulin

FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik for Adults With Type 2 Diabetes

Clinical trial data showing similar A1c control to daily basal insulin support a U.S. rollout of prefilled KwikPens in coming months.

U.S. Lawsuits and European Finding Focus Scrutiny on GLP‑1 Drugs and Rare Vision Loss

Employers Trim Coverage of GLP-1 Weight-Loss Drugs

FDA Clears Libre Duo 10 Day as First Wearable to Track Ketones and Glucose

Oral Semaglutide Linked to Fewer Heavy Drinking Days in Small Randomized Trial

Medicare Launches GLP‑1 Bridge to Offer Select Weight‑Loss Drugs for $50 a Month

Study Finds Common GLP‑1 Use and Misuse Among People With Eating Disorders

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

UC Irvine's Battery-Free Sweat Patch Regenerates to Track Four Biomarkers for 21 Days

New Data Tie GLP-1 Drugs’ Broad Benefits to Inflammation

Tirzepatide Linked to Lower Death and Heart Events After PCI and TAVR in New Real-World Analyses

GLP-1 Drugs Linked to Lower Addiction Risk and Harm in Large VA Study

Evolocumab Cuts First Cardiovascular Events by 31% in High‑Risk Diabetes Without Known Atherosclerosis

Senators Unveil Bipartisan INSULIN Act With $35 Cap and Uninsured Pilot

GLP-1 Weight-Loss Boom Is Reshaping Diets as Experts Urge Lifestyle Support

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

FDA Recalls Specific FreeStyle Libre 3 Sensors Over Faulty Low-Glucose Readings

After-Meal Blood Sugar Spikes Tied to 69% Higher Alzheimer’s Risk, Large Genetic Study Finds

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

FDA Issues Early Alert on Certain FreeStyle Libre 3 Sensors After False Low Readings Linked to Harm